To print: Select File and then Print from your browser's menu

Title: Carbamazepine Therapy May Increase Bone Turnover

URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12460249&dopt=Abstract

Epilepsia 2002 Dec;43(12):1488-1492. "Increased Bone Turnover in Prepubertal, Pubertal, and Postpubertal Patients Receiving Carbamazepine."
12/12/2002 09:26:07 AM
By Alison Palkhivala

Carbamazepine appears to increase bone turnover in paediatric patients, based on serum measurements of markers for bone formation and resorption. In a study led by A. Verrotti from the department of medicine, section of paediatrics, University of Chieti, Italy, investigators measured the bone turnover of 60 children with epilepsy being treated with carbamazepine. They stratified the patients according to pubertal stage and compared them to a control group of 60 healthy children, who were matched in terms of age and sex. Following two years of carbamazepine therapy, patients taking the drug had higher serum concentrations of markers for bone formation and bone resorption than patients not taking the drug. Despite these changes, all patients had normal vitamin D metabolism. Markers of bone formation measured were bone alkaline phosphatase, osteocalcin, carboxy-terminal peptide of type I procollagen and amino-terminal propeptide of type III procollagen. Markers of bone resorption measured were carboxy-terminal telopeptide of type I collagen and the urinary cross-linked N-telopeptides of type I collagen. According to the authors, carbamazepine may increase bone formation and resorption, and this effect appears to be independent of pubertal age.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12460249&dopt=Abstract

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.